Introduction
Auto-SCT is a frequently applied treatment modality for patients with multiple myeloma and relapsing lymphoma. 1, 2 However, in 30-50% of the patients the underlying malignant disorder relapses within 2-5 years after auto-SCT. Treatment options are then limited not only because of drug resistance of the tumor, but also because of the severe concurrent chemotherapy-induced pancytopenia. Several in vitro studies have shown that the impaired BM capacity might be related to intrinsic defects of the hematopoietic compartment reflected by a reduced clonogenic potential of the long-term culture initiating cells in conjunction with a shortening of telomeres. [3] [4] [5] After allo-SCT also a higher mitotic activity of BM CD34 þ /CD90 þ cells has been shown. 6 Recent studies in mice and humans have shown that the compartments of the hematopoietic stem cell and progenitor cells (common myeloid progenitor (CMP), granulocytemacrophage progenitor (GMP) and megakaryocyteerythroid progenitor (MEP)) can be defined phenotypically with certain surface markers. 7, 8 These phenotypically defined subpopulations are also verified by in vitro colony assays. In these assays the CMP fraction provided myeloid and erythroid colony formation whereas the GMP fraction generated exclusively myeloid colony formation. 9 In addition, the progenitors and more differentiated hematopoietic cells can be studied in vivo. Recent studies have shown that the cycling activity of the BM compartment can be visualized by using the PET tracer 3-fluoro-3-deoxy-Lthymidine ( 18 F-FLT PET). 10, 11 Distinct patterns of uptake have been shown. In myelodysplasia a significantly higher cycling activity of the BM compartment was noticed whereas in aplastic anemia a significant reduction in cycling activity was shown. 10 Combining both in vitro and in vivo experiments, important information can be obtained regarding the functionality of the hematopoietic stem cell compartment after auto-SCT.
The results of this study show that BM CD34 þ cells at 6-9 months after auto-SCT show a shift from CMP to a more GMP-enriched phenotype, a reduced colony frequency and a higher cycling activity compared with normal CD34 þ cells. These results were validated in vivo by showing a significantly higher uptake of 18 F-FLT in the BM compartment after auto-SCT.
Materials and methods

Patients
BM samples from patients and normal controls were obtained after informed consent according to the institutional guidelines. CD34 þ cells were isolated by EasySep immunomagnetic cell selection (StemCell Technologies, Vancouver, Canada) according to the manufacturer's instructions.
Flowcytometry analysis and sorting procedures
Sorting of the CD34 þ cells into progenitor fractions was performed on the basis of the combinatorial expression of cell surface Ags as previously reported. 9 CMPs were defined as CD34
The FACS analyses were performed on a FACS Calibur (Becton Dickinson (BD), Alpen a/d Rijn, The Netherlands). Antibodies were obtained from BD. Data were analyzed using WinList 3D (Verity Software House, Topsham, ME, USA) and FlowJo (Tri Star, Inc, Ashland, OR, USA) software.
Colony-forming cell (CFC) progenitor assay
The CFC assay was performed in 1.2% methylcellulose containing 30% FCS, 57.2 mM b-mercaptoethanol and 2 mM glutamine, supplemented with 20 ng/mL IL-3, 20 ng/mL IL-6, 20 ng/mL G-CSF, 20 ng/mL c-Kit ligand and 1 U/mL EPO (Cilag: Eprex, Brussels, Belgium) as previously described. 12 To define the in vitro cycling activity of the CFCs, CD34 þ cells were incubated with variable concentrations of cytarabine (Faulding Pharmaceuticals, Brussels, Belgium), that is, 5 Â 10 À7 M, 1Â 10 À6 M, 5Â 10 À6 M, 7.5Â 10 À6 M, 1 Â 10 À5 M, 5Â 10 À5 M and 1 Â 10 À4 M for 24 h and subsequently plated in the CFC assay. After 14 days the CFC colony number was counted with an inverted microscope.
Cell cycle analysis
For cell cycle analysis, Hoechst staining was performed. In brief, cells were resuspended at 1 Â 10 6 /mL in warm hematopoietic progenitor growth medium, 5 mg/mL Hoechst 33 342 (Sigma-Aldrich, Zwijndrecht, The Netherlands) was added and cells were incubated at 37 1C for 45 min. Medium was removed and cells were stained with antibodies for progenitor analysis. Washed cells were kept on ice until FACS analysis.
18 F-FLT PET 18 F-FLT was produced with a radiochemical purity of 495% and a specific activity of 410 TBq/mmol. 18 F-FLT in a dose of 400 MBq ( ± 10%) was administered i.v. as described. 10 To quantify BM expansion, we developed a simple scoring system in which one point is given for expansion in every one-third of the long bones, based on the well-known distribution of 18 F-FLT in the central skeleton and proximal part of the femoral and humeral bone. The 18 F-FLT uptake was also quantified using standardized uptake value analysis in patients and control subjects. We selected several sites of the axial skeleton to sample 18 F-FLT activity. The regions of interests used in standardized uptake value analysis were based on the mean value within the 50% isocontour's boundaries using a Siemens Leonardo workstation Forchheim, Germany. The control patients were patients with untreated non-small cell lung cancer or testicular cancer who had undergone 18 F-FLT PET for other studies with normal blood hematology values and had no signs of BM metastases at presentation or during 6 months of follow-up. In addition, the patients were free of chemotherapeutic or radiotherapeutic treatment. The protocols were approved by the institutional medical ethical committee of the University Medical Center Groningen.
Statistics
For analysis of overall and individual group differences, we used Kruskall-Wallis and Mann-Whitney U tests. For correlations, we used Spearman correlation. Differences with a P-value of p0.05 were considered statistically significant.
Results
Patients
This study included patients with relapsing lymphoma (n ¼ 5) treated with intensive chemotherapy and auto-SCT using BEAM as conditioning regimen, and multiple myeloma patients (n ¼ 11) treated with chemotherapy and auto-SCT using high-dose melphalan (200 mg/m 2 ) as conditioning regimen. The infused auto-SCT consisted of at least 4 Â 10 6 CD34 þ cells/kg (range 4.3-12.5 Â 10 6 ) with only three patients receiving o5 Â 10 6 CD34 þ cells/kg. The studied patients were analyzed at 6-9 months after auto-SCT. The peripheral blood cell counts showed a mean Hb level of 7.6 mmol/L (range 6.5-8.7), a mean leukocyte count of 6.9 Â Table 1 . BM cytology showed no abnormalities. There was no significant difference in age between patients after auto-SCT (median 52 years, range 42-63)) and controls (median 48 years, range 29-68) (P ¼ 0.1).
BM CD34
þ progenitor subsets after auto-SCT The isolated CD34 þ BM cells (n ¼ 8) were phenotypically characterized for the percentage of CMP, GMP and MEP and compared with the distribution pattern of normal BM CD34 þ cells (n ¼ 7). No significant difference was observed in the percentage of MEP in BM after auto-SCT vs normal controls (mean percentage 4.3%, 95% confidence interval (CI) 2.1-6.5 vs 2.6%, 95% CI 0.8-4.5, P ¼ 0.3). However, a significantly increased percentage of phenotypically defined GMP (mean percentage 51.8%, 95% CI 39.6-64.2 vs 27.6%, 95% CI 19.6-35.5, P ¼ 0.01) was observed, whereas a reduction in the phenotypically defined CMP fraction (mean percentage 3.7% 95% CI 0.7-6.9 vs 19.4% 95% CI 11.3-27.6, P ¼ 0.001) was shown after auto-SCT. A representative experiment is depicted in Figure 1 . Comparable results were observed in a limited number of patients studied with a follow-up time of 43 years as shown for a patient 10 years after auto-SCT (Supplementary Figure) . No distinct difference in progenitor subsets was observed between multiple myeloma or lymphoma patients.
To further characterize the CD34 þ cell fraction after auto-SCT, progenitor frequency was tested using the in vitro CFC assay. A decrease in CFC frequency per 10 3 plated CD34 þ cells was shown compared with normal CD34 þ BM cells (109±52 vs 185±56, P ¼ 0.008). In these CFC assays no significant difference was found in the colony distribution of colony-forming unit granulocyte/ monocyte and erythroid burst-forming units in BM after auto-SCT compared with normal BM. In CFC assays from BM after auto-SCT, the percentage of colony-forming unit granulocyte/monocyte colonies was 60.4% (compared with 55.5% for normal BM, P ¼ 0.67) and 39.1% for erythroid burst-forming unit colonies (compared with 41.4% for normal BM, P ¼ 0.78). The decrease in CFC frequency from CD34 þ cells after auto-SCT was not due to an impaired proliferative activity. Cell cycle analysis revealed a significantly higher fraction of CD34 þ cells in G2/S phase (mean 29%, 95% CI 19.1-38.4 vs 14%, 95% CI 1.6-25.7, P ¼ 0.03) and a reduced percentage of cells in G1 phase (mean 67%, 95% CI 56.4-78.2 vs 86%, 95% CI 73.9-98.4, P ¼ 0.03) compared with normal CD34 þ cells (Figure 2 ). It seemed that especially the GMP fraction of CD34 þ cells after auto-SCT showed a higher cycling activity (mean percentage 35%, 95% CI 27.7-43.0 in G2/S phase vs 19%, 95% CI 13.0-25.7, P ¼ 0.03), whereas no significant differences were observed for the MEP and CMP fractions. The higher cycling activity of the GMP fraction was also observed in BM cells of patients with a longer follow-up time. Analysis of the GMP fraction in a patient at 10 years after auto-SCT showed 36.7% of cells in G2/S phase. To verify whether the progenitor fraction within the CD34 þ fraction had an enhanced cycle activity and therefore would be more susceptible to chemotherapy-induced apoptosis, for 24 h and subsequently cultured in the CFC assay. Normal CD34 þ cells showed a 45% reduction in CFC frequency at a concentration of 5 Â 10 À5 M (n ¼ 4). Comparable results were observed with CD34 þ cells after auto-SCT (n ¼ 3) (reduction of 39%; NS). No significant difference was observed in the percentage of CD34 þ / CD38 low cells between patients after auto-SCT and normal controls. However, in the CD34 þ /CD38 low fraction also a higher cycling activity was observed after auto-SCT compared with normal controls ( Figure 1 ) (P ¼ 0.03), suggesting that also this fraction is affected by the auto-SCT procedure.
18
F-FLT PET scans in patients after auto-SCT Recent studies have shown that 18 F-FLT PET scan can be used to visualize the cycling activity of the BM compartment by which the degree of uptake is a reflection of the rate of DNA synthesis. 10, 11 The 18 F-FLT PET scans in 10 patients after auto-SCT showed a significant increase in standardized uptake values measured at different locations of the BM compartment (Figure 3) . The mean values of the left and right area were obtained in comparison to normal controls: femur 3.6 ± 0.7 vs 1.2 ± 0.5, Po0.001; crista 3.9±0.6 vs 2.2±0.5, Po0.001; lumbar 4 vertebral body 4.9±1.3 vs 3.1±0.9, Po0.005; thoracic 6 vertebral body 5.0 ± 0.6 vs 3.2 ± 0.9, Po0.001; and spine 4.7 ± 2.5 vs 3.9 ± 0.7, Po0.005. Moreover, a significant expansion of the BM compartment was noticed (expansion factor of 6 ± 2.5). Representative 18 F-FLT PET scans of a patient after auto-SCT and of a normal individual are shown in Figure 3B .
Discussion
This study shows that the auto-SCT procedure results in defects of myeloid progenitors at different levels. BM CD34 þ cells after auto-SCT show a phenotypic shift from CMP to GMP progenitors and have a reduced clonogenic potential. Moreover, these cells show an enhanced cycle activity in vitro, which could be confirmed in vivo by 18 F-FLT PET scanning.
It is remarkable that even though we observe enhanced proliferation of myeloid cells as determined by 18 F-FLT PET scanning as well as by cell cycle analysis of the GMP fraction, the steady-state peripheral blood cell counts seem 192K  128K  64K  256K  192K  128K  64K  256K  192K  128K  64K  256K  192K  128K Figure 1 Shift to a GMP-enriched phenotype in the BM compartment after auto-SCT. Representative FACS dot plots showing progenitor subsets of normal BM and BM at 6-9 months after auto-SCT. In BM after auto-SCT, the percentage of phenotypically defined GMP was increased, whereas a reduced percentage was observed in the CMP fraction. With Hoechst staining a higher cycling activity was observed in the CD34 þ /CD38 low and GMP subfractions of BM after auto-SCT compared with normal.
to be almost normal at 6-9 months after auto-SCT. Thus, there seems to be an imbalance in the hematopoietic compartment, by which under steady-state conditions the peripheral blood cell counts can be maintained up to normal levels, but at the expense of an increased proliferation rate. Although molecular mechanisms remain to be determined, it is conceivable that cell intrinsic as well as extrinsic factors are contributing to the observed phenotypes after auto-SCT. So far, no enhanced apoptosis was observed in BM cells after auto-SCT as determined by EM studies (E Vellenga, 2009 unpublished data). Several studies have shown an enhanced decline of telomere length after auto-SCT predominantly of the myeloid lineage. 5, 13 In aging telomerase knockout mice, enhanced proliferation and cycling activity of myeloid progenitors have been shown in conjunction with a preferential differentiation along the myeloid lineage with a significant increase in the GMP fraction. [14] [15] [16] Therefore, chemotherapy application and the auto-SCT procedure might have fastened the aging process in patients after auto-SCT, resulting in the shift to a GMP phenotype.
The enhanced cycling activity by CD34
þ cells is not restricted to auto-SCT. Patients at 6-12 months after allo-SCT also have an enhanced cycling activity of the CD34 þ cells, suggesting that the enhanced cycling activity is not only associated with the exposure of DNA-damaging agents. 6 It is therefore conceivable that the hematopoietic compartment undergoes a replicative stress response because of the infusion and engraftment of a limited number of cells. It is of interest whether alternative transplantation strategies might improve this situation by increasing the number of hematopoietic stem cells in the BM cavity by direct infusion of the SCT in the BM. Indeed studies in mice have shown that direct infusion of the stem cell transplant in the BM cavity has advantages compared with infusion i.v. 17, 18 Comparable results have been shown with cord blood transplantation in the setting of allo-SCT. 19, 20 Whether this approach will also reduce the replicative stress response in the auto-SCT setting requires further study.
In summary, this study shows that auto-SCT results in defects of the hematopoietic compartment after auto-SCT, characterized by a shift to a GMP-enriched phenotype, reduced clonogenic potential and enhanced in vitro and in vivo cycling activity.
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